Compare iShares MSCI South Africa ETF (EZA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI South Africa ETF trades at $62.85, while State Street SPDR S&P Biotech ETF trades at $151.74. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| EZA | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $81.60 | $164.28 |
52-Week Low | $53.05 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA is trading at $62.83, down 0.98% on the day, with a bearish technical outlook indicated by moving averages and overall momentum. The stock shows neutral oscillator readings but faces selling pressure according to ADX indicators. Recent corporate actions include a $1.43 dividend scheduled for June 2026, providing some income appeal despite current technical weakness.
The stock faces headwinds from bearish technical signals while lacking current fundamental data for comprehensive analysis. Investment opportunity exists through the upcoming dividend, but requires monitoring of earnings reports and financial metrics once available. Key risks include market volatility and the need for updated financial disclosures to assess true valuation.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
